Press Releases

CHICAGO, Dec. 10, 2019 /PRNewswire/ -- SullivanCotter, the nation's leading independent consulting firm in the assessment and development of total rewards programs and workforce solutions for the health care industry and not-for-profit sector, welcomes new Principal, Amber Duncan. She joins Nanci Hibschman

MOUNTAIN VIEW, Calif., Dec. 10, 2019 /PRNewswire/ -- Glooko, the global leader in diabetes data management, announced today that its Mountain View, California and Gothenburg, Sweden sites have received joint ISO 13485:2016 certification from accredited certification body Intertek Testing Services NA Ltd. T

SAN FRANCISCO, Dec. 10, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of

THOUSAND OAKS, Calif., Dec. 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced additional results from the primary analysis of the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) in p

DOYLESTOWN, Pa., Dec. 10, 2019 /PRNewswire/ -- Diverse Biotech, Inc. www.diversebiotech.com has announced it has successfully synthesized and progressed into pre-clinical testing

NASDAQ: CORV   TSX: CORV VANCOUVER, Dec. 10, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that NASDAQ and the Toronto Stock Exchange (TSX) have halted trading of the Company's common stock.  The U.S. Food and

CEDAR KNOLLS, N.J., Dec. 10, 2019 /PRNewswire/ -- MYOS RENS Technology, Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that it will launch its longevity business with the introduction

LITTLE FALLS, N.J., Dec. 10, 2019 /PRNewswire/ -- Cantel Medical Corp. (NYSE: CMD) today announced financial results for its first quarter ended October 31, 2019.

WALTHAM, Mass., Dec. 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to commence a Phase 2 expansion cohort based on encouraging clinical activity and a well-tolerated safety profile o

TEMPE, Ariz., Dec. 10, 2019 /PRNewswire/ -- Consumers that enroll or renew their coverage in 2020 with Ambetter from Arizona Complete Health